This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This strategic consolidation establishes PicnicHealth as the leading patient-centric evidence-generation partner within a rapidly evolving lifesciences landscape. By combining forces, we can unlock the potential of patient-centered studies and provide best-in-class solutions to support therapeutic development.”
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drugdevelopment, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Blockchain technology’s potential impact on the lifesciences industry (drugdevelopment, distribution and prescribing) is significant. It can impact the opioid crisis and improve tracking drugs in the supply chain.
Investments will focus on the next generation of pharma R&D to accelerate drugdevelopment, on new technology solutions enabling a more patient-centric approach in clinical trials, and on digital platforms uncovering new insights from clinical data for more personalized care pathways.
billion valuation in the last fundraising in early 2017, according to Lagniappe. Life-sciences companies recorded the strongest gains, Fenwick found, with their valuations rising 110% compared with their prior funding rounds. But key facets of its business didn’t develop as planned, say people familiar with the company.
We organize all of the trending information in your field so you don't have to. Join 48,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content